Medicinal herbs for hepatitis C virus infection

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2001, Pages

  Liu, Jian Ping ^a   Manheimer, Eric ^b   Tsutani, Kiichiro ^c   Gluud, Christian ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEPATITIS C; HUMAN; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HEPATITIS C, CHRONIC; HUMANS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS;

EID: 0035226427     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003183     Document Type: Article

References (88)

1. Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain M. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 1998;13(3):244-7.
2. Batey RG, Bensoussan A, Fan YY, Hossain MA, Bollipo S. Chinese herbal medicine lowers ALT in hepatitis C. A randomized placebo controlled trial report [AASLD abstract]. Hepatology 1996;24(4 Pt.2):404A.
3. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis. International Journal of Clinical Pharmacology, Therapy and Toxicology 1993;31(9):456-60.
4. Chen J, Han XY, Miao YX, Zhang SX, Fu SX, Liu ZM, et al. [Clinical study of Bingganling for treatment of hepatitis C]. Hebei Journal of Traditional Chinese Medicine 1998;20(3):137-8.
5. Han GP, Wang ZY, Peng SL. [Binggan capsule combined with interferon for treatment of 30 cases of hepatitis C]. Henan Journal of Traditional Chinese Medicine 1997;12(5):43-4.
6. Jiang YH. [Treatment of 20 cases of hepatitis C using a self-prescribed Yizhu oral liquid]. Journal of Nanjing University of TCM 1999;15(4):256.
7. Pei ZG, Liu YL, Zhao SM. [Therapeutic observation on Binggan decoction combined with interferon in 46 cases of hepatitis C]. The Practical Journal of Integrating Chinese with Modern Medicine 1996;9(7):444.
8. Raymond RS, Fallon MB, Abrams GA. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;129(10):797-800. [MEDLINE: 9841585]
9. van Rossum T GJ, Vulto AG, Hop W CJ, Brouwer JT, Niesters H GM, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999;14:1093-1099.
10. Xiao HQ, Luo RY, Wu WF, Deng TT. Effect of Gansu capsule on chronic hepatitis C. Journal of Guangzhou University of Traditional Chinese Medicine 1999;16(1):24-7.
11. Yu WJ. [Yi Er Gan decoction for treatment of 40 cases of hepatitis C]. New Journal of Traditional Chinese Medicine 1995;27(8):46-7.
12. Abe Y, Ueda T, Kato T, Kohli Y. Effectiveness of interferon glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 1994;52(7):133-138.
13. Akbar N, Tahir RA, Santoso WD, Soemarno, Sumaryono, Noer HM, et al. Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients. Chinese Medical Journal (Engl) 1998;111(3):248-251. [MEDLINE: 99302657]
14. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79(8):1494-500.
15. Cheng WP, Zhou ZG, Zhang JL, Liu Q, Wu BL, Liu YH, et al. [Treatment of 13 cases of viral hepatitis C using Bingganling]. Information on Traditional Chinese Medicine 1997;14(2):23.
16. Deng DS. [Songzhi granule for treatment of 30 cases of hepatitis C]. Hunan Journal of Traditional Chinese Medicine 1997;13(6):27-8.
17. Fujiwara K, Mochida S. Usefulness of traditional oriental medicine in the treatment of chronic viral hepatitis. Kanpo To Saishin Chiryo (in Japanese) 1994;3(2):116-120.
18. He JF. [Treatment of 30 cases of viral hepatitis C using Yu Gan Tang]. Hebei Journal of Traditional Chinese Medicine 1999;21(1):17-8.
19. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24(6):715-719.
20. Hirayama C, Okumura M, Tanigawa H, Yano M, Tujii T, Satoh S, et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Analysis of serum enzyme activities. Kan Tan Sui 1992;25(3):551-558.
21. Liang QM. [Qianggan Jiedu decoction for treatment of 26 cases of hepatitis C]. New Journal of Traditional Chinese Medicine 1996;28(10):48-9.
22. Lin P, Duan SH, Li JP. Treating 51 cases of type C hepatitis with buoshenggantai toupi tie. Henan Journal of Traditional Chinese Medicine and Pharmacy 1998;13(4):35-6.
23. Liu XY, Liu FC, Xu GX. [Songzhi granule for treatment of 139 cases of hepatitis C]. Hunan Journal of Traditional Chinese Medicine 1996;12(6):26-7.
24. Ma YM, Zhang ZC, Su M. 32 cases of C-hepatitis mainly treated with Xiao Chaihutang. Nei Mongol Journal of Traditional Chinese Medicine 1995;14(2):8.
25. Murray-Lyon I. Interferon (IFN) and ribavirin in conjunction with Chinese herbal medicines in the management of chronic hepatitis C. The National Research Register 2000, issue 4.
26. Murray-Lyon I. A prospective placebo controlled trial of adjunctive Chinese herbal medicine in the treatment of chronic hepatitis C. The National Research Register 2000, issue 4.
27. Nagao Y, Sata M, Suzuki H, Tanikawa K, Itoh K, Kameyama T. Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection. J Gastroenterol 1996;31:691-695.
28. Niu H, Li Y. [Binggan Fuyuan Tang for treatment of post-transfusion hepatitis C]. Jiangsu Journal of Traditional Chinese Medicine 1999;20(3):18.
29. Okuno T, Arai K, Shindo M. Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy. Nippon Rinsho 1994;52(7):139-43.
30. Qiu ZJ, Qiu JD. [Case report of treatment of hepatitis C using a self-prescribed suxiao Binggan Dan]. Liaoning Journal of Traditional Chinese Medicine 1997;24(6):277-8.
31. Sun MH. [Treatment of 48 cases of viral hepatitis C using Bingganjian]. Zhejiang Journal of Traditional Chinese Medicine 1996;31(4):149.
32. Sun JG, Tang L. [Therapeutic observation on chronic viral hepatitis C using self-prescribed Bingganning decoction]. Hebei Journal of Traditional Chinese Medicine 1998;20(6):328.
33. Tian LH, Tang CJ. [Touying Zhuangqi therapy for treatment of 37 patients with hepatitis C]. Clinical Journal of Anhui Traditional Chinese Medicine 1998;10(6):362-3.
34. Tsubota A, Kumada H, Arase Y, Chayama K, Saitoh S, Ikeda K, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomised controlled trial in 170 patients. Eur J Gastroenterol Hepatol 1999;11(10):1077-1083.
35. Wang LT, Ren JY, Wang TL, Chen JJ, Lei CD. Pathological study on the therapeutic effect of compound tinggan granula on chronic hepatitis C. Journal of Gastroenterology and Hepatology 1999;14(Suppl.):A320.
36. Wang LT, Ren JY, Wang TL, Lei CD, Chen JJ. Pathological study of the therapeutic effect of Compound Qinggan Granula on chronic hepatitis C. Chinese Journal of Hepatology 2000;8(2):91-93.
37. Wu CR, Lu DB, Li ZQ. [Treatment of 33 cases with hepatitis C by Chinese medical symptoms-differentiation]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 1994;4(1):44-5.
38. Xu HX. Chinese medical therapy of tonifying Qi, detoxifying, and activating blood circulation for treatment of 30 patients with hepatitis C. Acta Chinese Medicine and Pharmacology 1998;26(2):15.
39. Yamamura Y, Kotaki H, Tanaka N, Aikawa T, Sawada Y, Iga T. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbontetrachloride-intoxicated rats. Biopharmaceutics & Drug Disposition 1997;18(8):717-725.
40. Yamashiki M, Nishimura A, Huang XX, Nobori T, Sakaguchi S, Suzuki H. Effects of the Japanese herbal medicine 'Sho-saiko-to' (TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis. Developmental Immunology 1999;7(1):17-22.
41. Yan ZD, Li RD. [Therapeutic study on Qi Zhi granule for treatment of chronic hepatitis C]. Chinese Journal of Integrated Traditional and Western Medicine in Spleen and Stomach 2000;8(4):237-238.
42. Yao Z, Liu MC, Wang CD. Observation of therapeutic effect on '911 Granule' in treatment of chronic hepatitis B and C. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 1995;5(3):5-7.
43. Yao Z, Lu SL, Yao ZG, Yao YG, Liu MC, Wang CD. Observation of long-term therapeutic effect on '911 Granule' in treatment of chronic hepatitis B and C [abstract]. Hepatology 1998;28(4):710A.
44. Yin CJ, Li Y, Li YD, Cui AQ. [Therapeutic observation on Chinese herbal medicine for 31 cases of hepatitis C]. Journal of Shandong College of Traditional Chinese Medicine 1996;20(3):176-7.
45. You SX, Zhou M, Xue BY, Jiang JX, Fang TH, Jiang W, et al. Clinical study on C-hepatitis treated with Bingganling oral liquid. Journal of Traditional Chinese Medicine 1996;37(11):673-5.
46. Zhang JL, Wu PL, Ma GQ, Yang SQ, Zhou CZ. Bingganfu capsule for treatment of 40 cases of hepatitis C. Information on Traditional Chinese Medicine 1998;15(2):32.
47. Zhao XG. [Yanggan Rougan Lishi Jiedu for treatment of 50 cases of hepatitis C]. Henan Journal of Traditional Chinese Medicine 1999;19(6):46.
48. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992;327(27):1899-905.
49. Alter M. Epidemiology of hepatitis C. Hepatitis C Consensus Conference. Washington: Hepatitis Foundation International, 1997.
50. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79(8):1494-500.
51. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology 1995;21(3):639-44.
52. Blumberg BS. Hepatitis B virus: search for plant-derived antiviral. In: Tomlinson TR, Akerele D editor(s). Medical plants - their role in health and biodiversity. Philadelphia: University of Pennsylvania Press, 1998:7-12.
53. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005445]
54. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62. [MEDLINE: 2523562]
55. Council Directive 75/318/EEC. Council Directive of 20 May 1975 on the approximation of the laws of member states related analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products. Off J Eur Commun 1977;L147:1-12.
56. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
57. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Rompay MV, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 1998;280(18):1569-1575.
58. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325(2):98-104. [MEDLINE: 1646962]
59. Farrell GC. Consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about and what we still need to know. J Gastroenterol Hepatol 2000;15(Suppl.):E126-9.
60. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9(1):105-13.
61. Fleig WE, Morgan MY, Hölzer MA, and a European Multicenter Study Group. The Ayurvedic drug LIV.52 in patients with alcoholic cirrhosis. Results of a prospective, randomised, double-blind, placebo-controlled clinical trial. J Hepatol 1997;26(Suppl 1):127.
62. Geerts A, Rogiers V. Sho-Saiko-To: the right blend of traditional oriental medicine and liver cell biology. Hepatology 1999;29(1):282-4.
63. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. In: Leuschner U, James O, Dancygier H editor(s). Steatohepatitis (NASH and ASH) - FALK Symposium 121. Lancaster: Klüwer Academic Publisher, 2001:322-342.
64. Gottieb S. Chinese herb may cause cancer (news). BMJ 2000;320:1623.
65. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(3 suppl 1):15S-20S.
66. International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonisation Guidelines. Pennsylvania: Parexel/Barnett, 1997.
67. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696-9.
68. Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. European Respiratory Journal 1996;9(12):2691-6.
69. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1-12.
70. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-989.
71. Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, Bayer R. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 1999;282(1):28-9.
72. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
73. O'Hara M, Kiefer D, Farrell K, Kemper K. A review of 12 commonly used medicinal herbs. Archives of Family Medicine 1998;7(6):523-36.
74. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999;319(7224):1534-9.
75. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349(9055):825-32.
76. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 1998;12(3):199-205.
77. Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408-12.
78. Schuppan D, Jia J-D, Brinkhaus B, Hann EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999;30(4):1099-1104.
79. Seeff LB, Miller RN, Rabkin CS, Buskell BZ, Straley-Eason KD, Smoak BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132(2):105-11.
80. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural histology of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450-6.
81. Tomlinson B, Chan TY, Chan JC, Critchley JA, But PP. Toxicity of complementary therapies: an eastern perspective. J Clin Pharmacol 2000;40(5):451-6.
82. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16(3):273-81.
83. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998;19:159-66.
84. Vickers A. Recent advances: Complementary medicine. BMJ 2000;321:683-6.
85. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
86. Wang BE. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 2000;15(Suppl):E67-E70.
87. World Health Organisation. Hepatitis C. Weekly Epidemiological Record. Geneva, Swizerland 1997; Vol. 72, issue 10:341-8.
88. Zuin M, Battezzati PM, Camisasca M, Riebenfeld D, Podda M. Effects of a preparation containing a standardized Ginseng extract combined with trace elements and multivitamins against hepatotoxin-induced chronic liver disease in the elderly. Journal of International Medical Research 1987;15(5):276-81.